Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have been diagnosed with hepatocellular carcinoma (liver cancer), confirmed by imaging or tissue biopsy
• People whose liver cancer cannot be treated with surgery, a liver transplant, or local treatments aimed directly at the tumour
• People whose condition is considered appropriate for treatment with the medications Atezolizumab and Bevacizumab as part of standard care (confirm with trial site)
• People who have at least one tumour that can be measured on scans, according to standard measurement guidelines called RECIST 1.1
• People whose liver is still functioning reasonably well, as measured by a scoring system called Child-Pugh — specifically a score of A or B (with a maximum of 7 points)
• People who are relatively physically well and able to carry out daily activities, as rated by a standard scale called ECOG performance status 0 or 1

Who may not be able to join:

• People who have taken medications that suppress the immune system within the 6 months before starting the trial treatment
• People who have, or have had, a condition where the immune system attacks the body (an autoimmune or inflammatory disorder)
• People who have previously been treated with certain types of immune-based cancer therapies, including drugs that target CTLA-4, PD-1, PD-L1, or VEGF
• People who have tested positive for HIV
• People who have both hepatitis B and hepatitis C infections at the same time (note: people who previously had hepatitis C but no longer show the virus in their blood may still be eligible — confirm with trial site)
• People who have been found on a recent scope examination (within the past 12 months) to have enlarged veins in the food pipe or stomach that the investigator considers at risk of bleeding
• People who have ongoing nausea, vomiting, or a serious digestive condition, are unable to swallow tablets or capsules, or who have had significant bowel surgery that might affect how the body processes the study medication
• People who have blood pressure that remains too high (above 150/90 mmHg) despite medical treatment, or who have had serious heart or blood vessel complications related to high blood pressure
• People who have a history of serious kidney conditions involving protein leaking into the urine (nephrotic or nephritic syndrome)
• People who have taken antibiotic medicines (taken by mouth or injection throughout the body) within 2 weeks before starting the trial treatment
• People who have used probiotic products or supplements within 1 week before starting the trial treatment
• People whose liver cancer is a specific less common type, including fibrolamellar, sarcomatoid, infiltrative-type, or a mixed liver and bile duct cancer
• People who have had another separate primary cancer diagnosis
• People who have received a live vaccine within 30 days before starting the trial treatment
• People who are pregnant or breastfeeding
• People who have had a serious allergic reaction to Atezolizumab, Bevacizumab, vancomycin, or any similar medications or their ingredients
• People who are currently taking part in another interventional clinical trial
• People who are detained in an institution by a legal or official order
• People who do not have the legal capacity to consent for themselves
• People with a known allergy to any component of vancomycin, atezolizumab, or bevacizumab

Important: Always verify eligibility with the trial site directly before applying.